Gastrointestinal Cancer

Lenvatinib plus pembrolizumab showed early antitumor activity and tolerability in previously treated patients with advanced solid tumors.

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.

Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.

John Zalcberg, ​PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.

In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, futibatinib was shown to be efficacious and tolerable.

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Neoadjuvant nivolumab shrank tumors in 29% of patients with hepatocellular carcinoma at high risk for recurrence, which may kickstart the ablation effect of electroporation.

Allyson Ocean, ​MD, discusses the need for additional second-line therapies in metastatic pancreatic cancer. 

The safety and efficacy of ramucirumab administered after a frontline, non–sorafenib-based systemic therapy in hepatocellular carcinoma was consistent with data from the sorafenib-receiving intention-to-treat population of the phase 3 REACH-2 study.

The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

A retrospective analysis of data from the CELESTIAL trial has demonstrated the potential role for cabozantinib in patients with advanced hepatocellular carcinoma and Child-Pugh B liver cirrhosis.

AVENGER 500, a pivotal phase 3 clinical trial evaluating the efficacy and safety of devimistat for patients with metastatic pancreatic cancer, has achieved its target enrollment of 500 patients.

The FDA has approved copper Cu 64 dotatate injection for the localization of somatostatin receptor–positive neuroendocrine tumors.

Rutika J. Mehta, MD, MPH, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Jonathan Strosberg, MD, highlights key trials spanning gastrointestinal cancers, challenges faced in certain diseases, and the focus of future research efforts.

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular carcinoma.

The CXCR4 antagonist BL-8040 in combination with the PD-1 inhibitor pembrolizumab has been shown to elicit encouraging responses in patients with pancreatic ductal adenocarcinoma.